Voluntary announcement InSilico Medicine nominates peripheral-restricted VAV1 molecular glue degrader for potential treatment of autoimmune diseases
Filed with HKEX · Stock code 3696 · · 2 pages · English
Summary by 6ix AI
This announcement serves to update shareholders and potential investors on the latest developments within the company. The announcement includes a forward-looking statement cautioning that the future business developments mentioned may not be realized as expected.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
InSilico Medicine Cayman TopCo on 6ix
Earlier from InSilico Medicine Cayman TopCo
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement InSilico Medicine nominates next-generation small molecule GIPR antagonist for potential intervention of obesity and related disorders
- Voluntary announcement InSilico Medicine entered into an AI co-development collaboration with a contract value up to tens of millions of U.S. dollars to build and commercialize foundation models for biology
- Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study
- Voluntary announcement increase in shareholding by chairman of the board
Later from InSilico Medicine Cayman TopCo
All InSilico Medicine Cayman TopCo news releasesFollow InSilico Medicine Cayman TopCo into a list and get an email when it puts out news.
Follow InSilico Medicine Cayman TopCo